Clinical trial
Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR…
NCT00391066 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00391066 |
|---|---|
| Title | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) |
| Official title | A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia |
| Acronym | LUCID |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | FCR + Lumiliximab, FCR |
| Enrollment | 627 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Oct 23, 2006 |
| Last update posted | Oct 2, 2015 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, France, Germany, Greece, India, Israel and 11 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: